Jump to navigation

The University of Arizona Wordmark Line Logo White
UA Profiles | Home
  • Phonebook
  • Edit My Profile
  • Feedback

Profiles search form

Kathleen E Rodgers

  • Associate Director, Translational Neuroscience
  • Professor, Pharmacology
  • Professor, Clinical Translational Sciences
  • Member of the Graduate Faculty
  • Professor, BIO5 Institute
Contact
  • (520) 626-4114
  • Bioscience Research Labs, Rm. 473
  • Tucson, AZ 85721
  • krodgers@arizona.edu
  • Bio
  • Interests
  • Courses
  • Scholarly Contributions

Biography

  • Devens, B.H., Grayson, M.H. Imamura, T. and Rodgers, K.E. O,O,S-Trimethyl Phosphorothioate Effects on Immunocompetence, Pesticide Biochemistry and Physiology. 24: 251-259, 1985.
  • Rodgers, K.E., Grayson, M.H., Imamura, T. and Devens, B.H. In Vitro Effects of Malathion and O,O,S - Trimethyl Phosphorothioate on Cytotoxic T Lymphocyte Responses, Pesticide Biochemistry and Physiology. 24: 260-266, 1985.
  • Rodgers, K.E., Imamura, T. and Devens, B.H. Effects of Subchronic Treatment O,O,S-Trimethyl Phosphorothioate on Cellular and Humoral Immune Response Systems, Toxicology and Applied Pharmacology. 81: 310-318, 1985. PMID 3877352
  • Rodgers, K.E., Imamura, T. and Devens B.H. Investigations Into the Mechanisms of Immunosuppression Caused by Acute Treatment With O,O,S-Trimethyl Phosphorothioate I. Characterization of Immune Cell Populations Affected, Immunopharmacology. 10: 171-180, 1985. PMID 2939039
  • Rodgers, K.E., Imamura, T. and Devens B.H. Investigations Into the Mechanisms of Immunosuppression Caused by Acute Treatment With O,O,S-Trimethyl Phosphorothioate II. Effect on the Ability of Murine Macrophages to Present Antigen, Immunopharmacology. 10: 181-189, 1985. PMID 3833856
  • Koizumi, A., Hasegawa, L., Rodgers, K.E. and Ellefson, D. Walford, R.C. and Imamura, T. Influence of H-2 Haplotypes on Poly I: C Induction of Xanthine Oxidase and Poly IC Induced Decreases In P-450 Mediated Enzyme Activities, Biochemical and Biophysical Research Communications. 138: 246-253, 1986. PMID 3755596
  • Rodgers, K.E., Leung, N., Devens, B. and Ware, C.F. and Imamura T. Lack of Immunosuppressive Effects of Acute and Subacute Administration of Malathion on Murine Cellular and Humoral Immune Responses, Pesticide Biochemistry and Physiology. 25: 358-365, 1986.
  • Rodgers, K.E., Leung, N., Imamura, T. and Devens B.H. Rapid In Vitro Screening Assay For Immunotoxic Effects of Organophosphates and Carbamates, Pesticide Biochemistry and Physiology. 26: 292-301, 1986.
  • Rodgers, K.E., Imamura, T. and Devens, B.H. Organophosphorus Pesticide Immunotoxicity: Effects of O,O,S-Trimethyl Phosphorothioate on Cellular and Humoral Immune Response Systems, Immunopharmacology. 12: 193-202, 1986. PMID 3493228
  • Lew, M.W., Katt, E.L., Rodgers, K.E. and diZerega G.S. Alteration of Follicle Regulatory Protein Levels In Human Reproductive Disorders: Obstet. Gynecol. 70: 157-162, 1987. PMID 3601276
  • Rodgers, K.E., Leung, N., Ware, C.F. and Imamura T. Effects of O,O,S-Trimethyl Phosphorodithioate on Immune Function, Toxicology. 43: 201-216, 1987. PMID 3492784
  • Rodgers, K.E., Imamura, T. and Devens, B.H. Investigations Into the Mechanisms of Immunosuppression Caused by Acute Treatment With O,O,S-Trimethyl Phosphorothioate Generation of Suppressive Macrophages From Treated Animals. Toxicology and Applied Pharmacology. 88: 270-281, 1987. PMID 3494328
  • Bryant, S.M., M. Fukasawa, Rodgers KE, diZerega GS. Mediation of Post-Surgical Wound Healing by Macrophages: Growth Factors and Other Aspects of Wound Healing Progress Vol. 266: 273-290, 1988. PMID 3380849
  • Katt, E, Fujimori, K, Yanagihara D, Campeau J, Numazaki M, Holst P, Tonetta S, Rodgers KE, Westhoff G, Mishell D, Horenstein J, diZerega GS. Determination of Follicle Regulatory Protein Levels in Urine During the Normal Menstrual Cycle Using an Enzyme-Linked Immunosorbant Assay. The Journal of Clinical Endocrinology & Metabolism Vol. 66(6):1213-1219, 1988.
  • Fujimori, K., Rodgers, K.E., Nakamura, R.M., Katt, E., Yanagihara, D.L. and diZerega, G.S. Localization of Follicle Regulatory Protein In the Porcine Ovary. J. Histochem. Cytochem. 36: 589, 1988. PMID 3367045
  • Rodgers, K.E. and Ellefson, D.D. Effects of Acute Administration of O,O,S-Trimethyl Phosphorothioate on the Respiratory Burst and Phagocytic Activity of Splenic and Peritoneal Leukocytes. Agents and Actions. 24: 152-160, 1988. PMID 2841830
  • Rodgers, K.E., Ellefson, D.D., Girgis, W., Scott, L and. diZerega, G.S. Effects of Tolmetin Sodium Dihydrate on Normal and Post-Surgical Peritoneal Cell Function. International Journal of Immunopharmacology. 10: 111-120, 1988.
  • Rodgers, K.E., Grayson, M.H. and Ware, C.F. Inhibition of Cytotoxic T Lymphocytes and Natural Killer Cell Mediated Lysis by O,O,S-Trimethyl Phosphorodithioate Is at An Early Post-Recognition Step. Journal of Immunology. 140: 564-570, 1988. PMID 3257244
  • Rodgers, K.E., Leung, N. and Ware, C.F. Effects of Acute Administration of O,O,S-Trimethyl Phosphorodithioate on the Generation of Cellular and Humoral Immune Responses Following In Vitro Stimulation. Toxicology. 51: 241-253, 1988. PMID 3051516
  • Abe, H., Rodgers, K.E., Ellefson, D. and diZerega, G.S. Kinetics of Interleukin-1 Secretion by Murine Post-Surgical Peritoneal Macrophages. Journal of Surgical Research. 47: 178-182, 1989. PMID 2787874
  • Fukasawa, M., Yanagihara, D.L., Rodgers, K.E. and diZerega, G.S. The Mitogenic Activity of Peritoneal Tissue Repair Cells: Control by Growth Factors. Journal of Surgical Research. 47: 45-51, 1989. PMID 2739400
  • Fukasawa, M., Campeau, J.D., Yanagihara, L., Rodgers, K.E. and DiZerega, G.S. Mitogenic and Protein Synthetic Activity of Tissue Repair Cells: Control by the Postsurgical Macrophages, Journal of Investigative Surgery 2: 169-180, 1989. {
  • Fukasawa, M., J.D. Campeau, W. Girgis, S.M. Bryant, Rodgers, K.E. and diZerega, G.S. Production of Protease Inhibitors by Postsurgical Macrophages. Journal of Surgical Research. 46: 256-261, 1989. PMID 2493532
  • Rodgers, K.E., Haviland D.L. and Ware C.F. Protection From O,O,S-Trimethyl Phosphorothioate Induced Immune Suppression. Immunopharmacology. 17: 131-140, 1989. PMID 2767956
  • Rodgers, K.E., Montz, F.J., Condon, S., Scott, L., Fujimori, K. and DiZerega, G.S. Inhibition of Ovarian Cancer Cell Proliferation In Vivo and Incorporation of 3H-Thymidine In Vitro After Follicle Regulatory Protein Administration. Obstetrics & Gynecology. 73: 66-74, 1989. PMID 2909044
  • Rodgers, K.E., Stern, M.L. and C.F. Ware: Effects of Subacute Administration of O,O,S-Trimethyl Phosphorodithioate on Cellular and Humoral Immune Response Systems. Toxicology. 54: 183-195, 1989.
  • Abe, H., Rodgers, K.E., Campeau, J.D., Girgis, W. and diZerega, G.S.: Temporal Response of Leukocyte Accumulation In the Thoracic After Two Types of Surgical Injury. J. Investigative Surgery. 3: 51-63, 1990. PMID 2282349
  • Abe, H., Rodgers, K.E., Campeau, J.D., Girgis, W., Ellefson, D. and diZerega, G.S. the Effect of Intraperitoneal Administration of Sodium Tolmetin-Hyaluronic Acid on the Postsurgical Cell Infiltration In Vivo. Journal Surgical Research. 49: 322-327, 1990. PMID 2214740
  • Fukasawa, M., Campeau, J.D., Yanagihara, D.L., Rodgers, K.E. and diZerega, G.S. Regulation of Proliferation of Peritoneal Tissue Repair Cells by Peritoneal Macrophages. Journal of Surgical Research. 49: 81-87, 1990. PMID 2359298
  • Rodgers, K.E. and D.D. Ellefson. Modulation of Macrophage Protease Activity by Acute Administration of O,O,S-Trimethyl Phosphorothioate. Agents and Actions. 29: 277-285, 1990. PMID 2160188
  • Rodgers, K.E. and D.D. Ellefson: Modulation of Respiratory Burst Activity and Mitogenic Response of Human Peripheral Blood Mononuclear Cells and Murine Splenocytes by Malathion. Fundamental and Applied Toxicology. 14: 309-317, 1990. PMID 2318355
  • Rodgers, K.E.: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) In the Treatment of Postsurgical Adhesions, Progress In Clin.   Res. 358:119-130, 1990. PMID 2217487
  • Rodgers, K.E., Marks, J., Ellefson, D.D., Yanagihara, D., Tonetta, S.A., Vasiliev, S., Morrow, C. P., Montz, F. and diZerega, G.S. Follicle Regulatory Protein: A Novel Marker For Granulosa Cell Tumor Patients. Gynecologic Oncology. 37: 381-387, 1990. PMID 1693585
  • Rodgers, K.E., Bracken, K., Cox, G., Richer, L., Girgis W. and diZerega, G.S. Inhibition of Postsurgical Adhesions by Liposomes Containing Anti-inflammatory Drugs. International Journal of Infertility. 35: 315, 1990.
  • Rodgers, K.E., Girgis, W., Johns, D., diZerega, G.S. Intraperitoneal Tolmetin Prevents Postsurgical Adhesion Formation In Rabbits. International Journal of Infertility. 35: 40-45, 1990.
  • Abe, H., Rodgers, K.E., Ellefson, D. and diZerega, G.S. Kinetics of Interleukin-1 and Tumor Necrosis Factor Secretion by Rabbit Macrophages Recovered From the Peritoneal Cavity After Surgery. J. Investigative Surgery. 4: 141-151, 1991. PMID 2069924
  • Schook L.B., Bick P.H., Kowolenko M, Laskin D.L, Adam D.O., Rodgers K.E. Symposium of Macrophage-Xenobiotic Interactions-Modulation of Toxicity and Macrophage Functions. Fundamental and Applied Toxicology 17:1-6, 1991.
  • Albertson, B.D., Rodgers, K.E., Tomai, T.P., Nolan-Watson, K., Zinaman, M.J. and diZerega, G.S. Enhancement of Follicle Regulatory Protein Levels Accompany Reinitiation of Ovulatory Function After Parturition. Am J Obstet Gyn. 167: 158-162, 1992. PMID 1442919
  • Kuraoka, S., Campeau, J.D., Rodgers, K.E., Nakamura R.M. and diZerega, G.S. Effects of Interleukin 1 (IL-1) on Postsurgical Macrophage Secretion of Protease and Protease Inhibitor Activities. Journal of Surgical Research. 52: 71-78, 1992. PMID 1312652
  • Rodgers, K., Ellefson, D., Girgis, W. and diZerega, G.S. Protease Secretion and Protease Inhibitor Secretion Following In Vitro Exposure to Tolmetin, Agents and Actions, 36: 248-257, 1992 PMID 1326879.
  • Rodgers, K.E. and D.D. Ellefson: Mechanism of the Modulation of Murine Peritoneal Cell Function and Mast Cell Degranulation by Low Doses of Malathion. Agents and Actions. 35: 57-63, 1992.
  • Rodgers, K.E. and diZerega, G.S. Modulation of Peritoneal Re-Epithelialization by Postsurgical Macrophages. Journal of Surgical Research. 53: 542-548, 1992. PMID 1434606
  • Rodgers, K.E., Abe, H., Campeau, J.D., Ellefson, D.D., Girgis, W. and diZerega, G.S. In Vivo Administration of Tolmetin In Hyaluronic Acid Modulates Protease Secretion by Postsurgical Macrophages. Journal of Investigative Surgery. 5: 285-296, 1992. PMID 1472482
  • Rodgers, K.E., Girgis, W., and diZerega, G.S. Effect of Tolmetin Sodium Dihydrate on Adhesion Formation by Intraperitoneal Administration of Antineoplastic Agents. Cancer Chemotherapy and Pharmacology. 29: 248, 1992. PMID 1370766
  • Abe, H., Campeau, J.D., Rodgers, K.E., Ellefson, D.D., Girgis, W., and diZerega, G.S. Peritoneal Lavage Fluid Protease Levels After In Vivo Administration of Tolmetin In Hyaluronic Acid, Journal of Surgical Research. 55: 1-6, 1993. PMID 8412132
  • Kuraoka, S., Campeau, J.D., Rodgers, K.E., Nakamura, R.M. and diZerega, G.S. Modulation of Cytotoxic Activity of Resident Macrophages by Postsurgical Macrophages. Journal of Surgical Research. 53: 97-103, 1993. PMID 8412126
  • Rodgers, K.E. and diZerega, G.S. Function of Peritoneal Exudate Cells After Surgery, Journal of Investigative Surgery. 6: 9-23, 1993. PMID 8452827
  • LeGrand, E., Rodgers, K.E., Girgis, W., Struck, K., Campeau, J.D., diZerega, G.S., and Kiorpes, T.C. Efficacy of Tolmetin Sodium For Adhesion Prevention In Rabbit and Rat Models. Journal of Surgical Research. 56: 67-71, 1994. PMID 8277771
  • Rodgers, K.E., Ellefson, D.D., Girgis, W., and diZerega, G.S. Modulation of Postsurgical Cell Infiltration and Fibrinolytic Activity by Tolmetin In Two Species. Journal of Surgical Research. 56: 314-325, 1994. PMID 8152224
  • Wiseman, D.M., Huang, W.J., Johns, D.B., Rodgers, K.E., and diZerega, G.S. Evaluation of Models, Methologies, Devices and New Surgical Concepts: The Time Dependent Effect of Tolmetin Sodium In A Rabbit Uterine Adhesion Model. Journal of Investigative Surgery. 7: 527-532, 1994. PMID 7893639
  • LeGrand, E.K., Rodgers, K.E, Girgis, W., Campeau, J.D. and diZerega, G.S. Comparative Efficacy of Nonsteroidal Anti-Inflammatory Drugs and Anti-Thromboxane Agents In A Rabbit Adhesion Prevention Model. Journal of Investigative Surgery. 8: 187-194, 1995. PMID 7547726
  • Rodgers, KE. The Immunotoxicity of Pesticides In Rodents. Human and Experimental Toxicology. 14: 111-113, 1995.
  • Sikorski, E., Kipen, H.M., Fielder, N., Miller, C.M., Selner, J.D. and Rodgers, K.E. The Question of Multiple Chemical Sensitivity. Fundamental and Applied Toxicology. 24: 22-28, 1995. PMID 7713339
  • Abiko, M., Rodgers, K.E., Campeau, J.D., Nakamura, R.M. and diZerega, G.S. Alterations In Angiotensin II Receptor Levels In Full Thickness Excisional Wounds In Rat Skin. Wound Repair and Regeneration. 4: 363-367, 1996. PMID 17177733
  • Abiko, M., Rodgers, K.E., Campeau, J.D., Nakamura, R.M. and diZerega, G.S. Alterations In Angiotensin II Receptor Levels In Sutured Wounds In Rat Skin. Journal of Investigative Surgery, 9: 447-453, 1996. PMID 8981218
  • Rodgers, K.E. and Xiong, S. Contribution of Mast Cell Mediators and Histamine to Alterations In Macrophage Function After Malathion Administration. Fundamental Applied Toxicology. 33: 100-108, 1996.
  • Rodgers, K.E., St Amand, K. and Xiong, S. Effects of Malathion on the Humoral Immunity and Macrophage Function In Mast Cell Deficient Mice. Fundamental and Applied Toxicology. 31: 252-258, 1996.
  • Rodgers, K.E., Girgis, W., Campeau, J.D. and diZerega, G.S. Reduction of Adhesion Formation by Intraperitoneal Administration of A Recombinant Hirudin Analog. Journal of Investigative Surgery, 9: 388-391, 1996. PMID 8951662
  • DeCherney, A.H, Dougherty, W.R., Felix, J.C., Rodgers, K.E., Girgis, W., Abiko, M., diZerega, G.S. Expression of Cyclin Protein After Thermal Injury In A Guinea Pig Model. J Burn Care Rehabil. 18: 292-298, 1997. PMID 9261693
  • Johns, D.B., Rodgers, K.E., Donahoe, W.L., Kiorpes, T.C., and diZerega, G.S. Reduction of Adhesion Formation by Postoperative Administration of Ionically Crosslinked Hyaluronic Acid, Fertility and Sterility. 68: 37-42, 1997. PMID 9207581
  • Rodgers, K.E. and Xiong S. Effects of Acute Administration of Malathion by Oral and Dermal Routes on Serum Histamine Levels. International Journal of Immunopharmacology. 19: 437-41, 1997.
  • Rodgers, K.E. Effects of Oral Administration of Malathion on the Course of Disease In MRL-Lpr. J of Autoimmunity. 10: 367-373, 1997. PMID 9237800
  • Rodgers, K.E. and Xiong, S. Contribution of Inflammatory Mast Cell-Mediators to Alterations In Macrophage Function After Malathion Administration. Intl J Immunopharmacology. 19: 149156, 1997.
  • Rodgers, K.E. and Xiong, S. Effect of Administration of Malathion For 14 Days on Macrophage Function and Mast Cell Degranulation. Fund Appl Toxicol. 37: 95-99, 1997.
  • Rodgers, K.E. and Xiong, S. Effect of Administration of Malathion For 90 Days on Macrophage Function and Mast Cell Degranulation. Toxicology Letters. 93: 73-82, 1997.
  • Rodgers, K.E., Decherney, A.H., St. Amand, K.M., Dougherty, W.M., Felix J.C., Girgis, W. and diZerega, G.S. Histologic Alterations In Dermal Repair After Thermal Injury: Effects of Topical Angiotensin II. Burn Care and Rehabilitation. 18: 381-388, 1997. PMID 9313116
  • Rodgers, K.E., Johns, D., Girgis, W., Campeau, J.D., LeGrand, E. and diZerega, G.S. Reduction of Adhesion Formation With Hyaluronic Acid Following Peritoneal Surgery. Fertil & Steril. 67: 553-558,1997. PMID 9091346
  • Rodgers, K.E., Abiko, M., Girgis, W., St. Amand, K., Campeau, J. and diZerega, G.S. Acceleration of Dermal Tissue Repair by Angiotensin II. Wound Repair and Regeneration. 5: 175-183, 1997.
  • Rodgers, K.E., Klykken, P., Jacobs, J., Frondoz, C., Tomazic, V. and Zelikoff, J. Immunotoxicology of Medical Devices, Fund Appl Toxicol. 36: 1-14, 1997.
  • Rodgers, K.E., Girgis, W., Campeau, J.D. and diZerega, G.S. Reduction of Adhesion Formation by Intraperitoneal Administration of Anti-inflammatory Peptide 2. Journal of Investigative Surgery. 10: 31-36, 1997. PMID 9100172
  • Xiong, S., and Rodgers K.E. Effects of Malathion Metabolites on Degranulation of and Mediator Release by Human and Rat Basophilic Cells. J of Toxicology and Environ Health. 51: 101-117, 1997.
  • Okuyama, N., Rodgers, K.E., Wang, C.Y., Girgis, W., Oz, M., St.Amand, K., Pines, E., DeCherney, A.H., Rose, E.A., Cohn, D. and diZerega, G.S. Prevention of Retrosternal Adhesion Formation In A Rabbit Model Using A Bioresorbable Film of Polyethylene Glycol and Polylactic Acid. Journal of Surgical Research. 78: 118-22, 1998. PMID 9733628
  • Rodgers, K.E., Johns, D., Girgis W. and diZerega, G.S. Prevention of Adhesion Formation After Intraperitoneal Administration of Tolmetin and Hyaluronic Acid. Journal of Investigative Surgery. 11: 327-339, 1998. PMID 9654393
  • Rodgers, K.E., Cohn, D., Hotovely, A., Pines, E., Diamond, M.P. and diZerega, G.S. Evaluation of Polyethylene Glycol/Polylactic Acid Films on the Prevention of Adhesions In the Rabbit Adhesion Formation and Reformation Sidewall Models. Fertility and Sterility. 69: 408-18, 1998.
  • Rodgers, K.E., Girgis, W., St. Amand, K.M., Campeau, J. and diZerega, G.S. Reduction of Adhesion Formation by Intraperitoneal Administration of Lazaroid Formulations. Human Reproduction. 13: 2443-51, 1998. PMID 9806265
  • Rodgers, K.E., Girgis W., Campeau, J. and diZerega, G.S. Reduction of Adhesion Formation by Intraperitoneal Administration of Arg-Gly-Asp Containing Peptides. Fertility and Sterility. 70: 1131-1136, 1998. PMID 9848306
  • Rodgers, K.E., Girgis, W., Campeau, J. and diZerega, G.S. Reduction of Adhesion Formation by Intraperitoneal Administration of Various Anti-Inflammatory Agents. Journal of Investigative Surgery. 11: 327-339, 1998. PMID 9827650
  • Okuyama, N., Roda, N., Guerrero, A., Dougherty, W., Nguyen, T., diZerega, G.S. and Rodgers, K.E. Effect of Angiotensin II on the Viability and Vascularity of Random Flaps In A Rat Model. Annals Plastic Surgery. Res. 42: 313-319, 1998.
  • Okuyama, N., Wang, E., Rose, E.A., Rodgers, K.E., Cohn, D., Oz, M., Girgis, W., Roda, N., Pines, E. and diZerega, G.S. Reduction of Retrosternal Adhesions With Bioresorbable Polymer Films, Annals of Thoracic Surgery. 68: 913-918, 1999. PMID 10509983
  • Rodgers, K.E. Late Peritoneal Response to Infection and Injury: Adhesion Formation, Sepsis. 3: 317-325, 1999.
  • Cohen, M.D., Schook, L.B., Oppenheim, J.J., Freed, B.M., and Rodgers, K.E. Symposium overview: Alterations in cytokine receptors by xenobiotics. Toxicol Rev. 48: 163-69, 1999. PMID 10353307
  • Rodgers, K.E., Schwartz, H., Roda. N., Thornton, M., Kobak, W. and diZerega G.S. Effect of (CMC/PEO) Films Oxiplex™ Adhesion Formation and Reformation in Rabbit Models and Peritoneal Infection in a Rat Model. Fertility and Sterility. 73: 831-838, 2000. PMID 10731549
  • Jaibaji, M., Brody, G.S., Rodgers, K.E., Espinoza, T., Roda, N., Maldanado, S., Pines, E. and diZerega, G.S. A new model for experimental tendon adhesions in the chicken. Annals of Plastic Surgery. 44: 205-210, 2000.
  • Rodgers, K.E., Xiong, S., Espinoza, T., Roda, N., Maldonado, S. and diZerega, G.S. Angiotensin II Increases Host Resistance to Peritonitis. Clin Diag Lab Immuno. 7: 635-41, 2000.
  • Rodgers, K.E., Xiong, S., Steers, R. and diZerega, G.S. Effect of Angiotensin II on Hematopoietic Progenitor Cell Proliferation, Stem Cells. 18: 287-294, 2000. PMID 10924095
  • Verco, S.J., Peers, E.M., Brown, C.B., Rodgers, K.E., Roda, N., diZerega, G.S. Development of a novel glucose polymer solution (icodextrin) for adhesion prevention: pre-clinical studies. Hum Reprod. 15: 1764-1772, 2000. PMID 10920100
  • Rodgers, K.E., Xiong, S., Felix, J.C., Roda, R., Espinoza, T., Maldonado, S., diZerega, G.S.: Development of Angiotensin (1-7) as an Agent to Accelerate Dermal Regeneration. Wound Repair & Regeneration. 9: 238-247, 2001.
  • Rodgers, K.E., Xiong, S., diZerega, G.S. Accelerated Recovery from Irradiation Injury by Angiotensin peptides. Cancer Chemother Pharmacol. 49: 403-11, 2002. PMID 11976823
  • Rodgers, K.E., Xiong, S., diZerega, G.S. Effect of Angiotensin II and Angiotensin (1-7) on White Blood Cell Recovery after Intravenous Chemotherapy. Cancer Chemother Pharmacol. 51: 97-106, 2003.
  • Rodgers, K.E., Espinoza, T., Felix, J.C., Roda, N. Maldonado, S., diZerega, G.S. Acceleration of Healing, Reduction of Fibrotic Scar and Normalization Of Tissue Architecture by an Angiotensin Analogue, NorLeu3-A(1-7). Plastic Recon Surg. 111: 1195-206, 2003. PMID 12621191
  • Conroy, S.E., Baines, L., Rodgers, K.E., Deviren, F., Verco, S.J. Prevention of chemotherapy-induced intraperitoneal adhesion formation in rats by icodextrin at a range of concentrations. Gynecologic Oncology. 88: 304-08, 2003.
  • Rodgers, K.E., Roda, N., Felix, J.C., Espinoza, T., Maldonado, S., diZerega, G.S. Histological Evaluation of the Effects of Angiotensin Peptides on Wound Repair in Diabetic Mice. Experimental Dermatology. 12: 784-90, 2003. PMID 14714558
  • Rodgers, K.E., Robertson, J.T., Espinoza, T., Oppelt, W., Cortese, S., diZerega. G.S., Berg, R.A. Reduction of Epidural Fibrosis In Lumbar Surgery With Oxiplex. The Spine Journal. 3/4: 277-83, 2003. PMID 14589186
  • Rodgers, K.E., Verco, S.J.S., diZerega, G.S. Effects of intraperitoneal 4% icodextrin solution on the healing of bowel anastomoses and laparotomy incisions in rabbits. Colorectal Disease. 5: 324-30, 2003. PMID 12814410
  • Ellefson, D.D., Espinoza, T., Roda, N., Maldonado, S., Rodgers, K.E. Synergistic Effects of Co-Administration of Angiotensin 1-7 and Neupogen on Hematopoietic Recovery in Mice. Cancer Chemother Pharmacol. 53: 15-24, 2004. PMID 14569417
  • Singer AJ, McClain SA, Rodgers KE. Development of a Porcine Incisional Wound Model and Novel Scarring Scales. Acad Emerg Med. 2004;11:518.
  • Rodgers, K.E., Ellefson, D.D., Espinoza, T., Roda, N., Maldonado, S., diZerega, G.S. Effect of NorLeu3-A(1-7) on Scar Formation Over Time After Full Thickness Incision Injury in the Rat. Wound Repair Regen. 13:309-17, 2005. PMID 15953051
  • Rodgers, K.E., Oliver, J., diZerega, G.S. Phase I/II does escalation study of angiotensin 1-7 (A(1-7)) administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemother Pharmacol. 57: 559-68, 2006. PMID 16096787
  • Rodgers, K.E., Ellefson, D.E., Espinoza, T., Maulhardt, H., Roda, N., Maldonado, S., diZerega, G.S. Fragments of Nle3-Angiotensin(1-7) Accelerate Healing in Dermal Models. J Peptide Res. 66: Suppl 1:41-47, 2005. {
  • Rodgers K.E. Technology evaluation: Chrysalin, OrthoLogic. Current Opinion in Molecular Therapeutics 7:264-272, 2005 PMID 15977425.
  • Rodgers, K.E., Ellefson, D.E., Espinoza, T., Hsu, Y. diZerega, G.S. Mehrian-Shai, R. Expression of Intracellular Filament, Collagen and Collagenase Genes in Diabetic and Normal Skin After Injury. Wound Repair Regen.14:298-305, 2006. PMID 16808808
  • diZerega G.S. and Rodgers K.E. Reply Letter to the Editor (Altundag). Cancer Chemotherapy and Pharmacology 58:284-284, 2006.
  • diZerega, G.S., Cortese, S., Rodgers, K.E., Block, K.M., Falcone, S.J., Juarez, T.G., Berg, R. A Modern Biomaterial for Adhesions Prevention. J Biomedical Materials Research: Part B - Applied Biomaterials. 81: 239-50, 2007. PMID 16969823
  • Cooper, K., Young, J., Wadsworth, S., Cui, H., diZerega, G.S., Rodgers, K.E. Reduction of Post Surgical Adhesion Formation with Tranilast. J Surg Res. 141: 153-61, 2007. PMID 17560610
  • Hwang, J., Rodgers, K.E., Oliver, J.C., Schluep, T. alpha-Methylprednisolone Conjugated Cyclodextrin Polymer Based Nanoparticles For Rheumatoid Arthritis Therapy. Int J Nanomedicine. Online early publication June 2008.
  • Cui, H., Gensini, M., Kataria, R., Twaddle, T., Zhang, J., Wadsworth, S., Petrilli, J., K.E., diZerega, G.S., Cooper, K. Reducing post-surgical adhesions utilizing a drug-enhanced device: sodium carboxymethylcellulose aqueous gel/poly(p-dioxanone) and Tranilast. Biomed Mater. 4:15001, 2009
  • Petrilli, J., Wadsworth, S., Cooper, K., Rodgers, K.E., Siekerka, J., diZerega, G.S. Tranilast: a pharmaceutical candidate for reduction of adhesions using a novel approach. Semin Reprod Med 26:341-48, 2008. PMID 18756411
  • Heringer-Walther, S., Eckert, K., Schumacher, S-M., Uharek, L., Wulf-Goldenberg, A., Gembardt, F., Fichtner, I., Schultheiss, H-P., Rodgers K., Walther, T. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica, 94:857-60, 2009.

 

  • Roks AJ, Rodgers K, Walther T. Effects of the renin angiotensin system on vasculogenesis-related progenitor cells. Curr Opin Pharmacol. 2011 Apr;11(2):162-74.
  • Rodgers KE, Burleson FG, Burleson GR, Lewis KM, Wolfsegger MJ, and Redl H. A Two-Component Polyethylene Glycol Sealant as an Adhesion Prevention Device Does Not Influence Intraperitoneal Infection in a Refined Animal Model. American Journal of Obstetrics and Gynecology, 2010 Nov;203(5):494.e1-6. PMID 20810099
  • Eidenschink, L, diZerega, GS, Rodgers, KE, Bartlett, Loken, MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months, Cytometry Part B (Clinical Cytometry), 2011 82B:18-25.
  • Rodgers KE, Verco S, Bolton, LL, diZerega GS. Accelerated Healing of Diabetic Wounds by NorLeu3-Angiotensin II(1-7), Expert Opinion on Investigational Drugs, 2011 Nov;20(11):1575-81. Epub 2011 Oct 6.
  • Mordwinkin NM, Russell J, Burke AS, diZerega G, Louie SG, Rodgers KE. Toxicological and Toxicokinetic Analysis of Angiotensin (1-7) in Two Species, Journal of Pharmaceutical Sciences, 2012 Jan;101(1):373-380 doi: 10.1002/jps.22730. Epub 2011 Aug 19. PMID 221858825
  • Mordwinkin NM, Meeks CJ, Jadhav SS, Espinoza T, Roda N, DiZerega GS, Louie SG, Rodgers KE. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow. Endocrinology, 153(5):2189-97. Doi:10.1210/en.2011-2031. Epub 2012 March 20. PMID 22434085

 

  • Balingit, P; Armstrong, DG; Reyzelman, AM; Bolton, L; Verco, SJ; Rodgers, KE; diZerega, GS. Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Effectiveness of NorLeu3-A(1-7) in Treating Subjects with Diabetic Ulcers, Wound Repair and Regeneration, 2012 20:482-490. PMID 22672145
  • Rodgers KE, Espinoza TE, Roda N, Meeks CJ, Hill C, Louie SG, and diZerega GS. Accelerated Hematopoietic Recovery with Angiotensin-(1-7) after Total Body Radiation, International Journal of Radiation Biology, 2012 Jun;88(6):466-76. Epub 2012 Apr 30. PMID 22433112
  • Jadhav SS, Sharma N, Espinoza T, Roda N, Meeks C, Mordwinkin N, De Los Santos M, DiZerega G, Hill C, Louie SG and Rodgers KE. Effects of Combined Radiation and Thermal Injury on Renin Angiotensin System. Wound Repair and Regeneration, 2013 Jan-Feb;21(1):131-40. doi: 10.1111/j.1524-475X.2012.00867.x. Epub 2012 Dec 11. PMID 23231670
  • Mordwinkin NM, Ouzounian JG, Yedigarova L, Montoro, MN, Louie SG and Rodgers, KE. Alteration of endothelial function markers in women with gestational diabetes and their fetuses. Journal of Maternal-Fetal & Neonatal Medicine 2013 Mar;26(5):507-12. doi: 10.3109/14767058.2012.736564. Epub 2012 Nov 9. PMID 23046386.
  • McKarns SC, Kerkvliet NI, Dean JH, Bonn MB, Cohen MD, Franko J, Laiosa MD, Lawrence BP, Luebke RW, Luster MI, Miller PG, Palmer RK, Pfau JC, Raman P, Regal JF, Rodgers KE, Schondelmeyer RS, Zhang X, and Burns-Naas LA. Immunotoxicology: Fifty years of global scientific progress. Journal of Immunotoxicology, Volume 9, Number 4, December 2012, pp. 339-340. PMID: 23078377
  • Pham H, Schwartz BM, Delmore JE, Reed E, Cruickshank S, Drummond L, Rodgers KE, Peterson KJ and diZerega GS. Pharmacodynamic stimulation of thrombogenesis by angiotensin 1-7 in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2013 Apr;71(4):965-72. doi: 10.1007/s00280-013-2089-x. Epub 2013 Jan 31. PMID 23370663
  • Hajjar, I and Rodgers KE. Do Angiotensin Receptor Blockers Prevent Alzheimer's Disease?, Current Opinions in Cardiology, 28(4):417-425, July 2013.
  • Rodgers, KE, Espinoza TB, Roda N, Meeks CM, and diZerega GS. Angiotensin-(1-7) Synergizes with Colony Stimulating Factors in Hematopoietic Recovery. Cancer Chemotherapy and Pharmacology, 72(6):1235-1245, 2013. doi: 1007/s00280-013-2312-9. Epub 2013 October 7. PMID 24091850
  • Shah, M, Edman, MC, Janga SR, Shi P, Dhandhukia J, Liu, S, Louie, SG, Rodgers, KE, MacKay JA, Hamm-Alvarez, SF. A rapamycin-binding protein polymer nanoparticle shows potent therapeutic activity in suppressing autoimmune dacryoadenitis in a mouse model of Sjogren’s syndrome. Journal of Controlled Release 171(3):269-279, 2013 doi 1016/j.conrel.2013.07.016. Epub 2013 Jul 23.
  • Rodgers, KE and diZerega, GS. The Local Renin Angiotensin System in Stem Cells. Frontiers in Cellular Endocrinology, 4:157(1-7), 2013. PMID: 24167502
  • Rodgers, KE, Peterson, KJ, Maulhardt, HA and diZerega, GS. Multilineage Hematopoietic Recovery following Angiotensin (1-7) Administration, Expert Opinion in Investigational Drugs, 23(4):551-9, 2014. doi: 10.1517/13543784.2014.891015. Epub 2014 Feb 20. PMID: 24555825
  • Jadhav SS, Espinoza T, Roda N, Meeks C, Mordwinkin N, Hill C, Louie SG and Rodgers KE. Effects of Combined Radiation and Thermal Injury on Apoptosis and Inflammation. Apoptosis, doi: 1007/s10495-015-1116-2. Epub 2015 March 17.
  • Rodgers, KE, Bolton LL, Verco, S, diZerega GS. NorLeu3-Angiotensin 1-7 [DSC127] As a Therapy for the Healing of Diabetic Foot Ulcers. Advances in Wound Care Jun1;4(6):339-245
  • Papinska A, Mordwinkin NM, Meeks CJ, Jadhev SS, Rodgers KE. Angiotensin-(1-7) administration benefits cardiac and renal health as well as progenitor cells in type 2 diabetes, British Journal of Pharmacology, 2015. June 15 doi 1111/bph.13225.
  • Rodgers, KE. Preclinical and clinical development of angiotensin peptides (Mas/Ang(1-7)/ACE-2): Future Clinical Applications. Protective Arm of the Renin Angiotensin System, Elsevier Press, 287-292, 2015.
  • Larsen, RA, Rodgers, KE, Kast WM, Da Silva D, Altomstone, R, Meeks C, diZerega GS, and Leedom, JM. Topical Mucosal Vaccination with Angiotensin(1-7) and Feline Immunodeficiency Virus Induces Secretory IgA Responses. Journal of Medical Microbiology & Diagnosis, 4:179, 2015. doi 10.4172/21610703.1000179
  • Yardley, MM, Huynh N, Rodgers KE, Alkana, RL and Davies DL. Oral delivery of Ivermectin using a fast dissolving oral film: Implications for repurposing Ivermectin for alcohol use disorders. Alcohol 49(6):553-9, 2015. doi: 10.1016/j.alcohol.2015.03.006 Epub 2015 May 29. PMID 26095588
  • Asatryan L, Khoja S, Rodgers KE, Alkana RL, Tsukamoto Hand Davies DL. Chronic ethanol exposure combined with high-fat diet results in P2X7 receptor up-regulation and parallel neuroinflammation and neurotoxicity in C57BL/6J mice. Journal of Neuroimmunology, 285:169-179, 2015. doi: 10.1016/j.neuroim.2015.06.007. Epub 2015 Jun 20. PMID 26198936
  • Irwin, RW, Solinsky, CM, Loya CM, Salituro FG, Rodgers, KE, Bauer, G, Rogawski, MA, Brinton, RD, Allopregnanolone Preclinical acute pharmacokinetic and pharmacodynamics studies to predict tolerability and efficacy for Alzheimer’s disease. PLOS One, 2015, June 3;10(6):e0128313 doi: 10.137/journal.pone.0128313. eCollection 2015.
  • Papinska A, Mordwinkin NM and Rodgers KE. Regulatory perspectives on the development of small molecules for cardiac regeneration. “Tissue engineering of the heart: from in vitro models to regenerative solutions” Advanced Drug Delivery Reviews. pp:S0169-409X(15)00143-X, 2015. doi:10.1016/j.addr.2015.06.013 PMID 26150343
  • Aboye, T, CJ Meeks, S. Majumder, A. Shekhtman, K. Rodgers, JA Camarero. Design of a MCoTI-based cyclotide with angiotensin 1-7 like activity. Molecules 2016, 21, 000, doi 10.3390.
  • Papinska A, Soto M, Meeks C, and Rodgers KE. Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacological Research 107:372-380. doi:10.1016/j.phrs.2016.02.026
  • Abdallah WF; Louie SG; Zhang Y, Rodgers KE, Sivok E, diZerega, GS, Humayun, MS. Stimulating Healing with NorLeu3-Angiotensin (1-7) Following Full-Thickness Corneal Injury in Rabbits. Invest. Ophthalmol. Vis. Sci. 2016 57(4): 2187094. doi: 10.1167/iovs.15-18515. PMID: 27116546 .
  • Rodgers KE, Espinoza T, Kim L, Meeks CJ, and diZerega GS. Novel model for Combined Radiation Injury in Guinea Pigs and mitigation of effects by NorLeu3-Angiotensin-(1-7), International Journal of Radiation Biology. 2017. 92: dio.org/10.1080/09553002.2016.1186302.
  • Soto M, Bang SI, McCombs J, Rodgers KE. Renin Angiotensin System Modifying Therapies are Associated with Improved Pulmonary Health. Clinical Diabetes and Endocrinology. 2017. 3:6-10.  doi: 10.1186/s40842-017-0044-1. eCollection 2017. PMID: 28702260. 
  • Nation, DA, Tan A, Dutt S, McIntosh EC, Yew B, Ho JK, Blanken AE, Jang JY, Rodgers KE, Gaubert A. Circulating progenitor cells correlate with member, posterior cortical thickness, and hippocampal perfusion. J. Alzheimers Dis. 2018. 61(1):91-101. doi: 10.3233/JAD-170587. PMID 29103037
  • Rodgers K. and Jadhav S. The application of mesenchymal stem cells to treat thermal and radiation burns. Adv. Drug Deliv. Rev. 2018. 123:75-81.doi: 10.1016/j.addr.2017.10.003.
  • GaffneyK, Weinberg M, Soto M, Louie S, Rodgers K. Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression, Hematologica, Hematologica, Jul. 2018, haematol.2018.193771; DOI:10.3324/haematol.2018.1931. PMID: 29976741.
  • Papinska AM and Rodgers KE. Long-term administration of angiotensin (1-7) to db/db mice reduces oxidative stress damage in the kidneys and prevents renal dysfunction. Oxidative Medicine and Cellular Longevity, 2018 Oct 23;2018:1841046. doi: 10.1155/2018/1841046. eCollection 2018. PMID: 30425780; PMCID: PMC62187
  • Reddy R, Liu S, Asante I, Parikh P, Rodgers K, Liebler J, Borok A, Baydur A, Louie S. Circulating Angiotensin Peptides Levels in Acute Respiratory Distress Syndrome Correlate with Clinical Outcomes: A Pilot Study. PLOS, 2019 Mar 7;14(3):e0213096. doi: 10.1371/journal.pone.0213096. eCollection 2019. PMID: 30845246
  • Lund BT, Stone R, Levy AM, Lee S, Rodgers KE, Kelland EE. Reduced Disease Severity Following Therapeutic Treatment with Angiotensin 1-7 in a Mouse Model of Multiple Sclerosis, Neurobiology of Disease, 2019 Jul;127:87-100. doi: 10.1016/j.nbd.2019.02.018. Epub 2019 Feb 25.
  • Hay M, Polt R, Heien MH, Vanderah T, Largent-Milnes, T, Rodgers K, Victor SL, Thompson, AL, Bartlett M, Doyle K, Konhilas JP. A Novel Angiotensin-(1-7)-glycoslylated Mas Receptor Agonist for Treating Inflammation Related Memory Dysfunction, Journal of Pharmacology and Experiment Therapeutics, J Pharmacol Exp Ther. 2019 Apr;369(1):9-25. doi: 10.1124/jpet.118.254854. Epub 2019 Feb 1. PMID: 30709867
  • Mak M, Lam C, Pineda SJ, Lou M, Xu LY, Meeks C, Lin C, Stone R, Rodgers K, Mitani G. Pharmacogenetics of Warfarin in a Diverse Patient Population. Journal of Cardiovascular Pharmacology and Therapeutics, 2019 Nov;24(6):521-533. doi: 10.1177/1074248419843530. Epub 2019 May 7. PMID: 31064211

Degrees

  • Ph.D. Biomedical Sciences
    • University of California, Riverside, California, United States

Work Experience

  • University of Arizona, Tucson, Arizona (2017 - Ongoing)

Licensure & Certification

  • Diplomat of the American Board of Toxicology, American Board of Toxicology (1992)

Related Links

Share Profile

Interests

Teaching

ImmunologyRegulatory SciencesDrug DevelopmentToxicology

Research

• Wound Healing• Hematopoiesis• Cardiovascular Disease, hypertension and myocardial Infarction• Involvement of Adult Stem Cells in Tissue Regeneration• Translational Research• Mitigation of Radiation Induced Injury• Metabolic Syndrome and Diabetes• Neurodegeneration and repairNeuroinflammation• Renin Angiotensin System• Regenerative Medicine and Drug Development 

Courses

2024-25 Courses

  • Translational Research in AD 2
    CTS 641B (Spring 2025)
  • Directed Research
    PHCL 692 (Fall 2024)
  • Dissertation
    PHCL 920 (Fall 2024)
  • Translational Research in AD 1
    CTS 641A (Fall 2024)

2023-24 Courses

  • Directed Research
    PHCL 692 (Spring 2024)
  • Dissertation
    PHCL 920 (Spring 2024)
  • Thesis
    PHCL 910 (Spring 2024)
  • Directed Research
    PHCL 692 (Fall 2023)
  • Dissertation
    PHCL 920 (Fall 2023)
  • Research
    PHCL 900 (Fall 2023)

2022-23 Courses

  • Directed Research
    PHCL 692 (Spring 2023)
  • Dissertation
    PHCL 920 (Spring 2023)
  • Thesis
    CTS 910 (Spring 2023)
  • Directed Research
    PHCL 692 (Fall 2022)
  • Dissertation
    PHCL 920 (Fall 2022)

2021-22 Courses

  • Independent Study
    PHCL 499 (Summer I 2022)
  • Directed Research
    PHCL 692 (Spring 2022)
  • Dissertation
    PHCL 920 (Spring 2022)
  • Independent Study
    PHCL 499 (Spring 2022)
  • Thesis
    CTS 910 (Spring 2022)
  • Translational Research in AD 2
    CTS 641B (Spring 2022)
  • Directed Research
    PHCL 692 (Fall 2021)
  • Dissertation
    PHCL 920 (Fall 2021)
  • Translational Research in AD 1
    CTS 641A (Fall 2021)

2020-21 Courses

  • Senior Capstone
    BIOC 498 (Summer I 2021)
  • Directed Research
    PHCL 692 (Spring 2021)
  • Dissertation
    PHCL 920 (Spring 2021)
  • Independent Study
    PHCL 499 (Spring 2021)
  • Research
    PHCL 900 (Spring 2021)
  • Senior Capstone
    BIOC 498 (Spring 2021)
  • Independent Study
    PHCL 499 (Winter 2020)
  • Directed Research
    PHCL 692 (Fall 2020)
  • Dissertation
    PHCL 920 (Fall 2020)

2019-20 Courses

  • Research
    PHCL 900 (Spring 2020)
  • Research Seminar
    PHCL 696A (Spring 2020)
  • Senior Capstone
    BIOC 498 (Spring 2020)
  • Thesis
    PHCL 910 (Spring 2020)
  • Translational Research in AD 2
    CTS 641B (Spring 2020)
  • Research
    PHCL 900 (Fall 2019)
  • Research Seminar
    PHCL 696A (Fall 2019)
  • Senior Capstone
    BIOC 498 (Fall 2019)
  • Translational Research in AD 1
    CTS 641A (Fall 2019)

2018-19 Courses

  • Directed Research
    BIOC 492 (Spring 2019)
  • Introduction to Research
    MCB 795A (Spring 2019)
  • Research Seminar
    PHCL 696A (Spring 2019)
  • Senior Capstone
    BIOC 498 (Spring 2019)
  • Directed Research
    BIOC 492 (Fall 2018)
  • Directed Research
    CHEM 492 (Fall 2018)
  • Research Seminar
    PHCL 696A (Fall 2018)
  • Senior Capstone
    BIOC 498 (Fall 2018)

2017-18 Courses

  • Directed Research
    BIOC 492 (Spring 2018)
  • Introduction to Research
    MCB 795A (Spring 2018)

Related Links

UA Course Catalog

Scholarly Contributions

Journals/Publications

  • Reyes-Reyes, E. M., Brown, J., Trial, M. D., Chinnasamy, D., Wiegand, J. P., Bradford, D., Brinton, R. D., & Rodgers, K. E. (2024). Vivaria housing conditions expose sex differences in brain oxidation, microglial activation, and immune system states in aged hAPOE4 mice. Experimental brain research.
    More info
    Apolipoprotein E ε4 allele (APOE4) is the predominant genetic risk factor for late-onset Alzheimer's disease (AD). APOE4 mouse models have provided advances in the understanding of disease pathogenesis, but unaccounted variables like rodent housing status may hinder translational outcomes. Non-sterile aspects like food and bedding can be major sources of changes in rodent microflora. Alterations in intestinal microbial ecology can cause mucosal barrier impairment and increase pro-inflammatory signals. The present study examined the role of sterile and non-sterile food and housing on redox indicators and the immune status of humanized-APOE4 knock-in mice (hAPOe4). hAPOE4 mice were housed under sterile conditions until 22 months of age, followed by the transfer of a cohort of mice to non-sterile housing for 2 months. At 24 months of age, the redox/immunologic status was evaluated by flow cytometry/ELISA. hAPOE4 females housed under non-sterile conditions exhibited: (1) higher neuronal and microglial oxygen radical production and (2) lower CD68 microglia (brain) and CD8 T cells (periphery) compared to sterile-housed mice. In contrast, hAPOE4 males in non-sterile housing exhibited: (1) higher MHCII microglia and CD11bCD4 T cells (brain) and (2) higher CD11bCD4 T cells and levels of lipopolysaccharide-binding protein and inflammatory cytokines in the periphery relative to sterile-housed mice. This study demonstrated that sterile vs. non-sterile housing conditions are associated with the activation of redox and immune responses in the brain and periphery in a sex-dependent manner. Therefore, housing status may contribute to variable outcomes in both the brain and periphery.
  • Lohman, T., Sible, I., Kapoor, A., Engstrom, A. C., Alitin, J. P., Gaubert, A., Rodgers, K. E., Bradford, D., Mather, M., Han, S. D., Thayer, J. F., & Nation, D. A. (2023). Blood pressure variability, central autonomic network dysfunction and cerebral small vessel disease in APOE4 carriers. medRxiv : the preprint server for health sciences.
    More info
    Increased blood pressure variability (BPV) is a risk factor for cerebral small vessel disease (CSVD) and neurodegeneration, independent of age and average blood pressure, particularly in apolipoprotein E4 () carriers. However, it remains uncertain whether BPV elevation is a cause or a consequence of vascular brain injury, or to what degree injury to the central autonomic network (CAN) may contribute to BPV-associated risk in carriers.
  • Marshall, A. J., Gaubert, A., Kapoor, A., Tan, A., McIntosh, E., Jang, J. Y., Yew, B., Ho, J. K., Blanken, A. E., Dutt, S., Sible, I. J., Li, Y., Rodgers, K., & Nation, D. A. (2023). Blood-Derived Progenitor Cells Are Depleted in Older Adults with Cognitive Impairment: A Role for Vascular Resilience?. Journal of Alzheimer's disease : JAD, 93(3), 1041-1050.
    More info
    Depletion of blood-derived progenitor cells, including so called "early endothelial progenitor cells", has been observed in individuals with early stage Alzheimer's disease relative to matched older control subjects. These findings could implicate the loss of angiogenic support from hematopoietic progenitors or endothelial progenitors in cognitive dysfunction.
  • Branigan, G. L., Brinton, R. D., Kim, Y. J., Rodgers, K. E., & Soto, M. (2021). Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy.. Alzheimer's & dementia (New York, N. Y.), 7(1), e12174. doi:10.1002/trc2.12174
    More info
    The impact of menopausal hormone therapy (HT) on age-associated Alzheimer's and neurodegenerative diseases (NDDs) remains unresolved. To determine the effect of HT, formulation, type, and duration on risk of NDDs, a retrospective analysis was performed using a 10-year Humana claims dataset..Study population included women aged 45 years or older with or without claim records of HT medications. Patients diagnosed with NDDs including Alzheimer's disease (AD), Parkinson's disease (PD), dementia, multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS) were identified. Relative risk (RR) ratios and 95% confidence intervals (CI) for combined NDDs, or AD, PD, dementia, MS, and ALS were determined. Cumulative hazard ratios were determined to investigate the association between HT and NDDs at different age groups..In 379,352 women with or without claim records of HT, use of HT was associated with significantly reduced risk for combined NDDs (RR 0.42, 95% CI 0.40-0.43, P < 0.001). Average follow-up time was 5.1 [2.3] years. Formulations containing natural steroids 17β-estradiol and/or progesterone were associated with greater reduction in NDD risk. Oral- HT users showed significantly reduced RRs (0.42, 0.41-0.44, P < 0.001) for combined NDDs compared to non-HT users. The RRs for transdermal-HT users were significantly decreased for all-cause dementia (0.73, 0.60-0.88, P = 0.001) and MS (0.55, 0.36-0.84, P = 0.005). Greatest reduction in risk of NDD, AD, and dementia emerged in patients aged 65 years or older. Further, the protective effect of long-term therapy (>1 year) on combined NDDs, AD, PD, and dementia was greater compared to short-term therapy (≤1 year)..HT was associated with reduced risk of all NDDs including AD and dementia, with greater duration of therapy and natural steroid formulations associated with greater efficacy. These findings advance precision HT to prevent NDDs including AD.
  • Rodgers, K. E. (2020). Endothelial progenitor cells are depleted in older adults with cognitive impairment and white matter volume loss: Molecular and cell biology/vascular factors. Alzheimer's & Dementia, 16, e046352. doi:https://doi.org/10.1002/alz.046352
    More info
    Correlation of reduced angiogenic cells and white matter loss.
  • Rodgers, K. E. (2021). Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy.. Alzheimer's Dementia, e12174. doi:https://doi.org/10.1002/trc2.12174
    More info
    Effects of hormone replacement therapy on neurodegenerative diseases
  • Rodgers, K. E. (2021). Increased Levels of Circulating Angiogenic Cells and Signaling Proteins in Older Adults with Cerebral Small Vessel Disease.. Frontiers in Aging Neuroscience. doi:doi.org/10.3389/fnagi.2021.711784
    More info
    Effects of MCI on the number of circulating angiogenic cells
  • Rodgers, K. E. (2020). Hormone Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes: A Retrospective Patient Cohort Analysis. JAMA Open Network, 3(3), e201541. doi:doi:10.1001/jamanetworkopen.2020.1541
  • Rodgers, K. E. (2020). Safety, tolerability and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer’s disease: A phase 1 single and multiple ascending dose clinical phase 1b/2a trial. Alzheimer's Dement, 6(1), e12107. doi:doi: 10.1002/trc2.12107. eCollection 2020.
  • Rodgers, K. E. (2020). Studies on CRMP2 SUMOylation-deficient transgenic mice identify sex-specific NaV1.7 regulation in the pathogenesis of chronic neuropathic pain. Pain, 161(11), 2629-2651. doi:doi: 10.1097/j.pain.0000000000001951
  • Rodgers, K. E. (2020). Targeting the Renin-Angiotensin System to Reduce Systemic Lupus Erythematosus Related Pathologies in MRL-lpr Mice. Frontiers in Immunology, 11, 1572. doi:doi: 10.3389/fimmu.2020.01572. eCollection 2020
  • Mak, M., Lam, C., Pineda, S. J., Lou, M., Xu, L. Y., Meeks, C., Lin, C., Stone, R., Rodgers, K., & Mitani, G. (2019). Pharmacogenetics of Warfarin in a Diverse Patient Population. Journal of cardiovascular pharmacology and therapeutics, 24(6), 521-533.
    More info
    Many warfarin-related genotypes have shown to impact the average daily warfarin (ADW) dose requirements; however, information in non-Caucasian populations is limited.
  • Rodgers, K. E. (2019). Circulating Angiotensin Peptides Levels in Acute Respiratory Distress Syndrome Correlate with Clinical Outcomes: A Pilot Study. PLOS. PLOS.
  • Rodgers, K. E. (2019). Reduced Disease Severity Following Therapeutic Treatment with Angiotensin 1-7 in a Mouse Model of Multiple Sclerosis. Neurobiology of Disease.
  • Soto, M., Gaffney, K. J., & Rodgers, K. E. (2019). Improving the Innate Immune Response in Diabetes by Modifying the Renin Angiotensin System. Frontiers in immunology, 10, 2885.
    More info
    Patients with Type 2 Diabetes Mellitus (T2DM) suffer from a higher incidence and severity of pulmonary infections. This is likely due to immune impairment and structural abnormalities caused by T2DM-induced oxidative stress (OS) and chronic inflammation. Modulation of the Renin Angiotensin System (RAS) through blockade of the actions of angiotensin II (AII), or inducing the protective pathway, has the potential to reduce these pathological pathways. The effects of Angiotensin 1-7 [A(1-7)] and NorLeu-A(1-7) [NorLeu], ligands of the protective RAS, on the innate immune response were evaluated in the mouse model of T2DM. Only NorLeu treatment reduced the structural pathologies in the lung caused by T2DM. A decreased in bactericidal activity and phagocytosis in diabetic animals was also observed; both A(1-7) and NorLeu treatment restored these functions. Myeloid progenitor CFUs were reduced and neutrophil/progenitor OS was increased in saline-treated mice, and was reversed by A(1-7) and NorLeu treatment. These results demonstrate the adverse effects of diabetes on factors that contribute to pulmonary infections and the therapeutic potential of protective RAS peptides. Overall, RAS-modification may be a viable therapeutic target to treat diabetic complications that are not addressed by glucose lowering drugs.
  • Soto, M., Gaffney, K., & Rodgers, K. E. (2019). Improving the Innate Immune Response in Diabetes by Modifying the Renin Angiotensin System. Frontiers in Immunology.
  • Stone, R., Lui, L., Levy, A., Louie, S., Rodgers, K. E., Kelland, E., & Lund, B. (2019). Activation of the protective arm of the renin angiotensin system in demyelinating disease. Journal of Neuroimmune Pharmacology.
  • Gaffney, K. J., Rodgers, K. E., Weinberg, M., & Soto, M. H. (2018). Development of angiotensin II (1-7) analog as an oral therapeutic for the treatment of chemotherapy-induced myelosuppression. Haematologica, haematol.2018.193771.
  • Rodgers, K. E. (2018). Circulating progenitor cells correlate with member, posterior cortical thickness, and hippocampal perfusion. J. Alzheimers Dis., 61(1), 91-101. doi:10.3233/JAD-170587
  • Rodgers, K. E. (2018). Long-term administration of angiotensin (1-7) to db/db mice reduces oxidative stress damage in the kidneys and prevents renal dysfunction.. Oxidative Medicine and Cellular Longevity. doi:10.1155/2018/1841046
  • Rodgers, K. E. (2018). The application of mesenchymal stem cells to treat thermal and radiation burns. Adv. Drug Deliv. Rev, 123, 75-81. doi:10.1016/j.addr.2017.10.003
  • Solinsky, C. M., Rogawski, M. A., Rodgers, K. E., Irwin, R. W., Brinton, R. D., & Bauer, G. (2016). COMPARATIVE PHARMACOKINETIC ASSESSMENT OF ALLOPREGNANOLONE TO DEVELOP A REGENERATIVE THERAPEUTIC FOR MILD COGNITIVE IMPAIRMENT AND EARLY ALZHEIMER’S DISEASE. Alzheimers & Dementia, 12(7), P430-P430. doi:10.1016/j.jalz.2016.06.820
  • Irwin, R., Solinsky, C., Loya, C., Salituro, F., Bauer, G., Rodgers, K. E., Rogawski, M., & Brinton, R. (2015). Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease.. PLoS One, 3(10).

Poster Presentations

  • Rodgers, K. E., Falk, T., Bernard, K., & Lopez-Smith, K. (2023, Fall). The Impact of Diabetes Therapies Leading to Subsequent Parkinson’s Disease Using Health Claims Database. . Sixth Annual Conference on Native American Nutrition..

Reviews

  • Rodgers, K. E. (2020. Countermeasure & therapeutic: A(1-7) to Treat Acute Respiratory Distress Syndrome due to COVID-19 Infection(p. 1470320320972018). Journal of the Renin-Angiotensin-Aldosterone System.

Profiles With Related Publications

  • Roberta Brinton
  • Kevin J Gaffney
  • Torsten Falk

 Edit my profile

UA Profiles | Home

University Information Security and Privacy

© 2024 The Arizona Board of Regents on behalf of The University of Arizona.